Merck & Co. Inc. (MRK) Financial News - Siemens Chief Loescher, Executives Win Extensions to Contracts

Merck & Co. Inc. (MRK)

Siemens Chief Loescher, Executives Win Extensions to Contracts

Quote: drugmaker Merck & Co. to replace CEO Klaus Kleinfeld as the Munich-based manufacturer was engulfed in allegations of kickbacks and bribes tied to projects in more than a dozen countries. In addition to exorcising corrupt practices, Loescher has scaled back Siemens’s operations to focus on industrial, energy and health-care customers. The reorganization has included selling the telecommunications division on which Siemens was founded and creating a fourth division targeting municipal infrastructure such as mass transit and energy distribution. Loescher has vowed Siemens will outgrow its main rivals to eventually become a company with 100 billion euros ($145 billion) in sales. Revenue will total 73.8 billion euros in the year ending Sept. 30 and rise to 84.8 billion euros in fiscal 2015, according to analyst estimates compiled by Bloomberg. Richard Weissrweiss5@bloomberg.net. bkammel@bloomberg.net. ...
Open whole article (external link)

Other Financial and Stock Market News concerning Merck & Co. Inc.

Merck & Co. Inc. Stock Summary

Merck & Co., Inc. provides products for human and animal health primarily in the United States. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; Addex Pharmaceuticals Ltd.; and Nuevolution A/S. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.